Advertisement
Screener

Viking Therapeutics, Inc. (VKTX) Graph

VKTX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Research and development $115.75M; Operating expenses $132.60M; Net income -$128.02M.
  • 2026-03-31: Revenue $0.00; Research and development $150.15M; Operating expenses $164.13M; Net income -$158.32M.
  • 2025-12-31: Revenue $0.00*; Research and development $153.46M*; Operating expenses $164.74M*; Net income -$157.66M*.
  • 2025-09-30: Revenue $0.00; Research and development $89.95M; Operating expenses $98.56M; Net income -$90.79M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

VKTX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$132.60MOperating income-$132.60MOther income, net$4.58MResearch & development$115.75MNet income-$128.02M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30$0.00$115.75M$132.60M-$128.02M
2026-03-31$0.00$150.15M$164.13M-$158.32M
2025-12-31$0.00*$153.46M*$164.74M*-$157.66M*
2025-09-30$0.00$89.95M$98.56M-$90.79M
2025-06-30$0.00$60.15M$74.57M-$65.56M
2025-03-31$0.00$41.39M$55.47M-$45.63M
2024-09-30$0.00$22.79M$36.56M-$24.94M
2024-06-30$0.00$23.77M$34.05M-$22.25M
2024-03-31$0.00$24.10M$34.07M-$27.36M
2023-09-30$0.00$18.38M$27.27M-$22.53M
2023-06-30$0.00$13.92M$23.74M-$19.23M
2023-03-31$0.00$11.01M$20.54M-$19.53M
2022-09-30$0.00$11.96M$16.20M-$15.77M
2022-06-30$0.00$13.54M$17.63M-$17.43M
2022-03-31$0.00$12.55M$16.25M-$16.10M
2021-09-30$0.00$10.79M$13.40M-$13.24M
2021-06-30$0.00$12.80M$15.54M-$15.38M
2021-03-31$0.00$11.54M$14.23M-$14.01M
2020-09-30$0.00$7.12M$9.84M-$9.29M
2020-06-30$0.00$7.78M$10.61M-$9.57M
2020-03-31$0.00$7.99M$10.95M-$9.69M
2019-09-30$0.00$5.28M$7.44M-$5.73M
2019-06-30$0.00$7.33M$9.57M-$7.67M
2019-03-31$0.00$4.50M$6.81M-$4.92M
2018-09-30$0.00$5.69M$7.39M-$6.60M
2018-06-30$0.00$5.22M$6.92M-$6.67M
2018-03-31$0.00$3.04M$4.80M-$3.55M
2017-09-30$0.00$3.46M$4.69M-$6.10M
2017-06-30$0.00$3.72M$4.98M-$5.17M
2017-03-31$0.00$3.53M$4.97M-$5.22M
2016-09-30$0.00$2.10M$3.26M-$3.81M
2016-06-30$0.00$2.37M$3.58M-$3.69M
2016-03-31$0.00$1.88M$3.27M-$3.59M
2015-09-30$0.00$2.51M$4.29M-$4.74M
2015-06-30$0.00$1.10M$2.63M-$7.87M
2015-03-31$0.00$138.97K$461.04K-$5.71M
2014-09-30$0.00$788.65K$1.15M-$261.80K
2014-06-30$0.00$21.24M$21.76M-$22.78M
2014-03-31$0.00$50.00K$209.74K-$228.94K

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30$0.00$265.90M$296.72M-$286.35M
2025-06-30$0.00$101.54M$130.04M-$111.19M
2024-06-30$0.00$47.87M$68.13M-$49.61M
2023-06-30$0.00$24.93M$44.28M-$38.76M
2022-06-30$0.00$26.10M$33.88M-$33.53M
2021-06-30$0.00$24.34M$29.77M-$29.39M
2020-06-30$0.00$15.77M$21.55M-$19.26M
2019-06-30$0.00$11.83M$16.38M-$12.60M
2018-06-30$0.00$8.26M$11.73M-$10.22M
2017-06-30$0.00$7.24M$9.95M-$10.39M
2016-06-30$0.00$4.25M$6.85M-$7.28M
2015-06-30$0.00$1.24M$3.09M-$13.58M
2014-06-30$0.00$21.29M$21.97M-$23.01M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30$0.00$191.50M$228.60M-$201.98M
2024-09-30$0.00$70.66M$104.68M-$74.55M
2023-09-30$0.00$43.30M$71.54M-$61.29M
2022-09-30$0.00$38.06M$50.07M-$49.31M
2021-09-30$0.00$35.13M$43.17M-$42.63M
2020-09-30$0.00$22.88M$31.40M-$28.55M
2019-09-30$0.00$17.11M$23.81M-$18.33M
2018-09-30$0.00$13.95M$19.12M-$16.82M
2017-09-30$0.00$10.71M$14.64M-$16.49M
2016-09-30$0.00$6.35M$10.11M-$11.09M
2015-09-30$0.00$3.75M$7.38M-$18.31M
2014-09-30$0.00$22.08M$23.11M-$23.27M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$0.00$344.95M$393.34M$1.00K-$359.64M
2024-12-31$0.00$101.64M$150.92M$1.00K-$109.96M
2023-12-31$0.00$63.81M$100.83M$1.00K-$85.89M
2022-12-31$0.00$54.23M$70.36M$1.00K-$68.87M
2021-12-31$0.00$44.98M$55.68M$2.00K-$54.99M
2020-12-31$0.00$31.93M$42.66M$0.00-$39.49M
2019-12-31$0.00$23.56M$32.69M$0.00-$25.78M
2018-12-31$0.00$19.04M$26.16M$0.00-$22.06M
2017-12-31$0.00$13.74M$19.07M$0.00-$20.58M
2016-12-31$0.00$9.00M$13.85M$0.00-$14.73M
2015-12-31$0.00$6.97M$12.00M(m)-$23.40M
2014-12-31$0.00$22.22M$23.47M(m)-$21.88M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
Veradermics, Inc (MANE)United States$4.839B
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
Organon & Co. (OGN)United States$3.603B17.03
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Erasca, Inc. (ERAS)United States$5.073B-19.96